Furthermore, a subgroup of patients with a hypermethylated CEA promoter had molecular and clinical features similar to the consensus molecular subtype 1 (CMS1) of colorectal cancer and presented with a poor prognosis. This evidence concerns the gene CEACAM5 and colorectal cancer.